Sabinsa Received New Zealand Patent for Forskolin

EAST WINDSOR, N.J.Sabinsa received a Grant of Patent from the New Zealand Patent Office, which describes processes to prepare derivatives of forskolin, namely, isoforskolin and 7-deacetylforskolin. New Zealand Patent No: 568652 Commercial Process for Making Forskolin and its Derivatives will be in force until Feb. 2, 2027.

This most recent patent is No. 63 in Sabinsas sizeable worldwide Intellectual Property portfolio. Additionally, Sabinsa has more than 50 pending patent applications worldwide. This patent furthers Sabinsas ability to protect their Intellectual Property as they make inroads into Oceania. The company recently received Product Information (PI) numbers for ForsLean® 10 percent and 20 percent from Australias TGA (Therapeutic Goods Administration), a division of the Australian Government Department of Health and Ageing, opening the way for ForsLean to enter the Australian market.